<乌鸦传媒>3D Mammograms Deliver Fewer False-Positive Findings However, half of women will have a false positive with annual screening with DBT Mar 25, 2022
<乌鸦传媒>Artificial Sweeteners Not So Sweet When It Comes to Cancer Risk Consumption of certain sugar alternatives linked to a 13% higher risk of developing cancer Mar 24, 2022
<乌鸦传媒>FDA OKs PARP Inhibitor as Adjuvant Therapy in Early Breast Cancer Olaparib (Lynparza) approved for high-risk patients with germline BRCA mutations Mar 14, 2022
<乌鸦传媒>Fluorescence-Guided Lumpectomy Shows Promise Imaging system reduced the need for re-excision in one-fifth of patients Mar 11, 2022
<乌鸦传媒>Androgen Receptor Agonist Active in Resistant ER+ Breast Cancer Also: Combination targets uncommon form of advanced HER2-mutant disease Mar 09, 2022
<乌鸦传媒>More Options for Precision Medicine in Metastatic Triple-Negative Breast Cancer Moving beyond chemotherapy to immunotherapy, PARP inhibitors, ADCs, combinations Mar 08, 2022
<乌鸦传媒>Chipping Away at the Dogma of Axillary Dissection in Breast Cancer Ongoing trials could help some women avoid even less-invasive sentinel lymph node biopsy Mar 07, 2022
<乌鸦传媒>Clinical Picture Brightens for HER2+ Breast Cancer With Brain Metastases New therapies breach blood-brain barrier to improve response, survival Mar 07, 2022
<乌鸦传媒>Honing the Indications for Adjuvant CDK4/6 Inhibition in Breast Cancer Defining high risk, considering role of Ki-67, BRCA mutations Mar 05, 2022
<乌鸦传媒>Older Patients With Low-Risk DCIS May Not Benefit From Surgery, Radiation Low rate of invasive recurrence, benefits of surgery and RT limited to patients under 70 Jan 05, 2022
<乌鸦传媒>Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancer No clear explanation for responses to HER2-targeted drug in HER2-negative tumors Dec 12, 2021
<乌鸦传媒>Neratinib-Based Combo Shows Efficacy in HR+, HER2-Mutant Metastatic Breast Cancer Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors Dec 12, 2021
<乌鸦传媒>'Watch and Switch' Strategy Extends PFS in HR-Positive Breast Cancer Progression-free survival doubled with treatment change based on monitoring for resistance marker Dec 10, 2021
<乌鸦传媒>CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancer Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant Dec 10, 2021
<乌鸦传媒>Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancer Updated PHOEBE trial results now show an overall survival benefit as well Dec 10, 2021
<乌鸦传媒>Benefits of Ovarian Suppression Persist in Premenopausal Breast Cancer Aromatase inhibitor-ovarian suppression tops tamoxifen strategies at 12-13 years Dec 09, 2021
<乌鸦传媒>Highly Mutated Breast Cancer Responds to Immunotherapy Nivolumab-ipilimumab combination associated with durable response in small study Dec 09, 2021
<乌鸦传媒>Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Site Second analysis shows OS benefit consistent across some intrinsic subtypes as well Dec 09, 2021
<乌鸦传媒>No Benefit With Metformin in Early Breast Cancer, Regardless of ER/PR Status However, there could be improved outcomes in HER2-positive patients Dec 08, 2021
<乌鸦传媒>Small PFS Boost With HDAC Inhibitor for Advanced HR-Positive Breast Cancer Chinese study contradicts U.S. trial that showed no benefit with entinostat add-on Dec 08, 2021
<乌鸦传媒>Black Women Most at Risk for Post-Surgical Lymphedema Black women seemed to have triple the odds of swelling after axillary lymph node dissection Dec 08, 2021
<乌鸦传媒>TROP2-Directed ADC Promising in Advanced Triple-Negative Breast Cancer Datopotamab deruxtecan turns in solid phase I results Dec 08, 2021
<乌鸦传媒>Genomic Profiling Improves Outcomes in Breast Cancer PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria Dec 07, 2021
<乌鸦传媒>Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancer Elacestrant led to significant improvement in all patients, ESR1-mutant subgroup Dec 07, 2021
<乌鸦传媒>Artificial Intelligence Tool Gets High Marks in Reading Mammograms Breast cancer screening results show AI's mettle in real-world dataset Dec 02, 2021
<乌鸦传媒>Year in Review: HER2-Positive Breast Cancer ADCs impress in second-line therapy, primary surgery debate, neoadjuvant PD-L1 falls short Nov 15, 2021
<乌鸦传媒>Low-Quality Mammography Leading to More Deaths in Black Women, Says Expert In cities like Chicago, Black women face higher breast cancer mortality versus white women Oct 26, 2021
<乌鸦传媒>No Survival Benefit for Internal Mammary Node Irradiation in Breast Cancer Women with medially or centrally located tumors may be candidates, however, says researcher Oct 26, 2021
<乌鸦传媒>More Evidence for Safety of Accelerated Radiation in Early Breast Cancer Studies show low toxicity with few recurrences Oct 25, 2021
<乌鸦传媒>Analysis Confirms Benefits of CDK4/6 Inhibition in Early Breast Cancer Reduced risk of recurrence, distant relapse with adjuvant abemaciclib Oct 20, 2021
<乌鸦传媒>'Modest' Link Between Infertility and Postmenopausal Breast Cancer Study finds increased risk for younger women, those with primary infertility Oct 19, 2021
<乌鸦传媒>First CDK4/6 Inhibitor OK'd for Early, High-Risk Breast Cancer Abemaciclib approved with endocrine therapy for hormone receptor-positive/HER2-negative disease Oct 13, 2021
<乌鸦传媒>Almost Half of Breast Cancer Patients Use Cannabis, Survey Finds Common reasons for use include pain, anxiety, nausea, and insomnia Oct 12, 2021
<乌鸦传媒>Standard of Care Hard to Beat in HER2-Negative Breast Cancer Swapping letrozole for fulvestrant, in combination with palbociclib, did not improve PFS Oct 07, 2021
<乌鸦传媒>Women With Very Dense Breasts Benefit From MRI Screening Dutch researchers recommend screening with MRI every 4 years Oct 01, 2021
<乌鸦传媒>Different Taxanes, Similar Outcomes in Advanced HER2-Positive Breast Cancer Results from docetaxel-based study appear applicable to paclitaxel, nab-paclitaxel Sep 29, 2021
<乌鸦传媒>What's Behind the Racial Differences in Women's Cancer Screening? Existing medical conditions and social factors are likely driving gaps, researchers found Sep 24, 2021
<乌鸦传媒>In RA, Little Risk for Recurrent Cancer With Biologic Treatment Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
<乌鸦传媒>Chemo Plus Keytruda Boosts Overall Survival in Advanced TNBC KEYNOTE-355 regimen offers "transformative treatment" in PD-L1-positive disease, expert says Sep 20, 2021
<乌鸦传媒>ADC Makes a Case for Role in Metastatic HER2-Positive Breast Cancer Improved progression-free survival in previously treated disease with trastuzumab duocarmazine Sep 20, 2021
